International Stem CellISCO -10.50%24 Days Payable is 28.93 as of Mar. 2026, which is 45% below its 10-year median of 52.79. GuruFocus rates ISCO with a GF Score™ of 24/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 700 Biotechnology companies, International Stem Cell ranks worse than 79.86% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, International Stem Cell's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Stem Cell Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Stem Cell's Days Payable distribution charts can be found below:
* The bar in red indicates where International Stem Cell's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
International Stem Cell's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Stem Cell (ISCO) has a Days Payable of 28.93 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on International Stem Cell and its competitors. This is 45% below median its historical median of 52.79. Over the past decade, International Stem Cell's Days Payable has ranged from 16.02 to 181.47. According to the industry distribution chart, International Stem Cell ranks #559 out of 700 companies in the Biotechnology industry, placing it in the top 79.9%.
Is International Stem Cell's Days Payable too high?
International Stem Cell's current Days Payable of 28.93 is 45% below median its 10-year median of 52.79. Over the past 10 years, this metric has ranged from a low of 16.02 to a high of 181.47. The Biotechnology industry median Days Payable is 113.10. International Stem Cell's value of 28.93 is 74.4% below this industry median. Based on the distribution chart, International Stem Cell ranks #559 out of 700 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, International Stem Cell has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's Days Payable compare to ZVSA and AXIM?
According to the Biotechnology industry distribution chart, International Stem Cell ranks #559 out of 700 companies for Days Payable. This places International Stem Cell in the lower half of its industry. The industry median Days Payable is 113.10. International Stem Cell's value of 28.93 is 74.4% below this benchmark. Historically, International Stem Cell's own Days Payable has ranged from 16.02 to 181.47 over the past decade. While the company's 10-year median is 52.79 vs. the industry median of 113.10, International Stem Cell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. International Stem Cell's current Days Payable of 28.93 is 74.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on International Stem Cell and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. International Stem Cell's current Days Payable is 28.93, which is 45% below median its own 10-year median of 52.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 37.7% above its estimated fair value. The current Days Payable is 28.93, which is 45% below median its 10-year median of 52.79 and 74.4% below the Biotechnology industry median of 113.10. International Stem Cell's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For International Stem Cell (ISCO), the current Days Payable is 28.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is International Stem Cell (ISCO) Overvalued in 2026?
Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued.
The current stock price of $0.18 is trading 37.7% above its estimated GF Value™ of $0.13.
GuruFocus considers International Stem Cell to be Significantly Overvalued.
Key valuation signals for ISCO:
Days Payable: 28.93 (45% below median its 10-year median of 52.79)
GF Value™: $0.13 vs. price of $0.18 (37.7% above fair value)
Industry Position: 74.4% below the Biotechnology median (#559 of 700)
No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
24GF Score
Get the complete analysis for ISCO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISCO has been successfully added to your 
